ECC 4703
Alternative Names: ECC-4703Latest Information Update: 13 Oct 2025
At a glance
- Originator Eccogene
- Class Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Dyslipidaemias
- Preclinical Obesity
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 06 Oct 2025 The US FDA clears IND application for ECC 4703 in Non-alcoholic-steatohepatitis
- 06 Oct 2025 Eccogene plans a phase II MOSAIC trial for Non alcoholic steatohepatitis (Combination therapy) in USA
- 28 Sep 2025 No recent reports of development identified for phase-0 development in Non-alcoholic-steatohepatitis(In volunteers) in USA (PO, Capsule)